Stock comparison
Halozyme Therapeutics
Sarepta Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
SRPT
Sarepta Therapeutics
Market cap
$1.77B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | SRPT | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 40D | HALO |
| Benjamin Graham | 83A | 47D | HALO |
| Philip Fisher |
Side-by-side metrics
| Metric | HALO | SRPT |
|---|---|---|
| Market cap | $8.1B | $1.77B |
| P/E (TTM) | 24.0x | 31.3x |
| EV/EBIT | 10.2x | - |
| ROIC (TTM) | 23.65% | -1.53% |
| Gross margin | 81.24% | 62.39% |
| Net margin | 23.13% | 2.98% |
| Revenue CAGR 5y | 33.23% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- ROIC (TTM)23.65%vs -1.53%+106%
- Net margin23.13%vs 2.98%+87%
- Market cap$8.1Bvs $1.77B+78%
- P/E (TTM)24.0xvs 31.3x
More like SRPT
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.